Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold ...

A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...